An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

The National Institute for Health and Care Excellence (NICE) has refused the 'miracle' drugs lecanemab and donanemab for use ...

The National Institute for Health and Care Excellence (NICE) has refused the 'miracle' drugs lecanemab and donanemab for use on the NHS as they are too expensive to justify.

Sarah Strauss. Bob Jones University — Oronoco: Abigail Graham. Cedarville University —: Johanna Trondson. Central Lakes College —: Johnny Tong. Concordia University —: Hope Nelson; Winona: Naa Kordai ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

In this video, Erica L. Mayer, MD, MPH, director of breast cancer clinical research at Dana-Farber Cancer Institute, discusses results of the TRADE study, which she presented at ASCO Annual ...

Juvena Therapeutics & Eli Lilly and Company ink research collaboration focused on muscle health: Redwood City, California Saturday, June 14, 2025, 15:00 Hrs [IST] Juvena Therapeut ...

The two products accounted for about 48% of Eli Lilly's most recent quarterly sales and drove most of the top-line growth.